Receptor tyrosine kinase inhibitors as potent weapons in war against cancers

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Receptor Tyrosine Kinases class I (RTK class I), also known as the EGF receptor family, are crucial transmembrane proteins regulating cell growth and survival.
• Dysregulation of RTK class I, including EGFR and HER2, is implicated in the development and progression of various human cancers.
• EGFR activation can result from overexpression, activating mutations, or ligand autocrine expression, while HER2 activation primarily stems from overexpression, leading to ligand-independent signaling.

Purpose of the Study:

• To review various inhibitors targeting members of the ErbB family, including RTK class I.
• To highlight the therapeutic potential of natural compounds, small molecules, and monoclonal antibodies against these receptors.
• To explore the development of novel anti-cancer molecules targeting RTK class I.

Main Methods:

• Literature review of inhibitors targeting RTK class I members (EGFR, HER2).
• Analysis of reported activities of natural compounds, small molecules, and monoclonal antibodies.
• Examination of clinical data for established and investigational ErbB inhibitors.

Main Results:

• EGFR and HER2 are validated clinical targets in oncology.
• Several EGFR inhibitors (Erlotinib, Gefitinib, Cetuximab) demonstrate clinical activity in non-small cell lung cancer and other solid tumors.
• Numerous ErbB inhibitors are in advanced clinical trials, individually or in combination therapies.

Conclusions:

• Targeted inhibition of RTK class I, particularly EGFR and HER2, represents a promising strategy in cancer therapy.
• A diverse range of inhibitors, including natural products and synthetic agents, show potential against ErbB family members.
• Further development of novel anti-cancer molecules targeting RTK class I holds significant promise for improved cancer treatment outcomes.